Stifel Reiterates ChemoCentryx (CCXI) at Buy, $85 PT, but Warns of Potential Slower Uptake of Tavneos
Tweet Send to a Friend
Stifel analyst Dae Gon Ha reiterated a Buy rating and $85.00 price target on ChemoCentryx (NASDAQ: CCXI), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
